img

Global Pulmonary Arterial Hypertension Treatment Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Pulmonary Arterial Hypertension Treatment Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death.
Due to the COVID-19 pandemic, the global Pulmonary Arterial Hypertension Treatment market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Vasodilators accounting for % of the Pulmonary Arterial Hypertension Treatment global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period.
The global key companies of Pulmonary Arterial Hypertension Treatment include GSK, Eli Lilly and Company, Pfizer Inc, Actelion Inc, United Therapeutic Corporation, SteadyMed Ltd, Gilead Sciences, Inc, Teva Pharmaceuticals Inc and Bayer AG, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Pulmonary Arterial Hypertension Treatment market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Pulmonary Arterial Hypertension Treatment landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Pulmonary Arterial Hypertension Treatment market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Pulmonary Arterial Hypertension Treatment market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Pulmonary Arterial Hypertension Treatment market. Readers of the report can become informed about current and future trends of the global Pulmonary Arterial Hypertension Treatment market and how they will impact market growth during the forecast period.



By Company


GSK
Eli Lilly and Company
Pfizer Inc
Actelion Inc
United Therapeutic Corporation
SteadyMed Ltd
Gilead Sciences, Inc
Teva Pharmaceuticals Inc
Bayer AG
Segment by Type
Vasodilators
Phosphodiesterase 5 (PDE 5) Inhibitors
Endothelin Receptor Antagonists (ERA)
Soluble Guanylate Cyclase (SGC) Stimulator

Segment by Application


Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Pulmonary Arterial Hypertension Treatment in global and regional level.
Chapter 3Detailed analysis of Pulmonary Arterial Hypertension Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pulmonary Arterial Hypertension Treatment revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Vasodilators
1.2.3 Phosphodiesterase 5 (PDE 5) Inhibitors
1.2.4 Endothelin Receptor Antagonists (ERA)
1.2.5 Soluble Guanylate Cyclase (SGC) Stimulator
1.3 Market by Application
1.3.1 Global Pulmonary Arterial Hypertension Treatment Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Pulmonary Arterial Hypertension Treatment Market Size (2018-2034)
2.2 Pulmonary Arterial Hypertension Treatment Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Pulmonary Arterial Hypertension Treatment Market Size by Region (2018-2024)
2.4 Global Pulmonary Arterial Hypertension Treatment Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Pulmonary Arterial Hypertension Treatment Countries Ranking by Market Size
3 Pulmonary Arterial Hypertension Treatment Competitive by Company
3.1 Global Pulmonary Arterial Hypertension Treatment Revenue by Players
3.1.1 Global Pulmonary Arterial Hypertension Treatment Revenue by Players (2018-2024)
3.1.2 Global Pulmonary Arterial Hypertension Treatment Market Share by Players (2018-2024)
3.2 Global Pulmonary Arterial Hypertension Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Pulmonary Arterial Hypertension Treatment Revenue
3.4 Global Pulmonary Arterial Hypertension Treatment Market Concentration Ratio
3.4.1 Global Pulmonary Arterial Hypertension Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension Treatment Revenue in 2022
3.5 Global Key Players of Pulmonary Arterial Hypertension Treatment Head office and Area Served
3.6 Global Key Players of Pulmonary Arterial Hypertension Treatment, Product and Application
3.7 Global Key Players of Pulmonary Arterial Hypertension Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Pulmonary Arterial Hypertension Treatment Breakdown Data by Type
4.1 Global Pulmonary Arterial Hypertension Treatment Historic Revenue by Type (2018-2024)
4.2 Global Pulmonary Arterial Hypertension Treatment Forecasted Revenue by Type (2024-2034)
5 Global Pulmonary Arterial Hypertension Treatment Breakdown Data by Application
5.1 Global Pulmonary Arterial Hypertension Treatment Historic Market Size by Application (2018-2024)
5.2 Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Pulmonary Arterial Hypertension Treatment Revenue by Company (2021-2024)
6.2 North America Pulmonary Arterial Hypertension Treatment Revenue by Type (2018-2034)
6.3 North America Pulmonary Arterial Hypertension Treatment Revenue by Application (2018-2034)
6.4 North America Pulmonary Arterial Hypertension Treatment Revenue by Country (2018-2034)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Pulmonary Arterial Hypertension Treatment Revenue by Company (2021-2024)
7.2 Europe Pulmonary Arterial Hypertension Treatment Revenue by Type (2018-2034)
7.3 Europe Pulmonary Arterial Hypertension Treatment Revenue by Application (2018-2034)
7.4 Europe Pulmonary Arterial Hypertension Treatment Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 UK
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue by Company (2021-2024)
8.2 Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue by Type (2018-2034)
8.3 Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue by Application (2018-2034)
8.4 Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Pulmonary Arterial Hypertension Treatment Revenue by Company (2021-2024)
9.2 Latin America Pulmonary Arterial Hypertension Treatment Revenue by Type (2018-2034)
9.3 Latin America Pulmonary Arterial Hypertension Treatment Revenue by Application (2018-2034)
9.4 Latin America Pulmonary Arterial Hypertension Treatment Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue by Company (2021-2024)
10.2 Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue by Type (2018-2034)
10.3 Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue by Application (2018-2034)
10.4 Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Pulmonary Arterial Hypertension Treatment Products and Services
11.1.4 GSK Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.1.5 GSK Pulmonary Arterial Hypertension Treatment SWOT Analysis
11.1.6 GSK Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Details
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Products and Services
11.2.4 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.2.5 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment SWOT Analysis
11.2.6 Eli Lilly and Company Recent Development
11.3 Pfizer Inc
11.3.1 Pfizer Inc Company Details
11.3.2 Pfizer Inc Business Overview
11.3.3 Pfizer Inc Pulmonary Arterial Hypertension Treatment Products and Services
11.3.4 Pfizer Inc Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.3.5 Pfizer Inc Pulmonary Arterial Hypertension Treatment SWOT Analysis
11.3.6 Pfizer Inc Recent Development
11.4 Actelion Inc
11.4.1 Actelion Inc Company Details
11.4.2 Actelion Inc Business Overview
11.4.3 Actelion Inc Pulmonary Arterial Hypertension Treatment Products and Services
11.4.4 Actelion Inc Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.4.5 Actelion Inc Pulmonary Arterial Hypertension Treatment SWOT Analysis
11.4.6 Actelion Inc Recent Development
11.5 United Therapeutic Corporation
11.5.1 United Therapeutic Corporation Company Details
11.5.2 United Therapeutic Corporation Business Overview
11.5.3 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Products and Services
11.5.4 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.5.5 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment SWOT Analysis
11.5.6 United Therapeutic Corporation Recent Development
11.6 SteadyMed Ltd
11.6.1 SteadyMed Ltd Company Details
11.6.2 SteadyMed Ltd Business Overview
11.6.3 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Products and Services
11.6.4 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.6.5 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment SWOT Analysis
11.6.6 SteadyMed Ltd Recent Development
11.7 Gilead Sciences, Inc
11.7.1 Gilead Sciences, Inc Company Details
11.7.2 Gilead Sciences, Inc Business Overview
11.7.3 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Products and Services
11.7.4 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.7.5 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment SWOT Analysis
11.7.6 Gilead Sciences, Inc Recent Development
11.8 Teva Pharmaceuticals Inc
11.8.1 Teva Pharmaceuticals Inc Company Details
11.8.2 Teva Pharmaceuticals Inc Business Overview
11.8.3 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Products and Services
11.8.4 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.8.5 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment SWOT Analysis
11.8.6 Teva Pharmaceuticals Inc Recent Development
11.9 Bayer AG
11.9.1 Bayer AG Company Details
11.9.2 Bayer AG Business Overview
11.9.3 Bayer AG Pulmonary Arterial Hypertension Treatment Products and Services
11.9.4 Bayer AG Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
11.9.5 Bayer AG Pulmonary Arterial Hypertension Treatment SWOT Analysis
11.9.6 Bayer AG Recent Development
12 Pulmonary Arterial Hypertension Treatment Market Dynamics
12.1 Pulmonary Arterial Hypertension Treatment Industry Trends
12.2 Pulmonary Arterial Hypertension Treatment Market Drivers
12.3 Pulmonary Arterial Hypertension Treatment Market Challenges
12.4 Pulmonary Arterial Hypertension Treatment Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Vasodilators
Table 3. Key Players of Phosphodiesterase 5 (PDE 5) Inhibitors
Table 4. Key Players of Endothelin Receptor Antagonists (ERA)
Table 5. Key Players of Soluble Guanylate Cyclase (SGC) Stimulator
Table 6. Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 7. Global Pulmonary Arterial Hypertension Treatment Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 8. Global Pulmonary Arterial Hypertension Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Pulmonary Arterial Hypertension Treatment Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 10. Global Pulmonary Arterial Hypertension Treatment Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 11. Global Pulmonary Arterial Hypertension Treatment Revenue by Players (2018-2024) & (US$ Million)
Table 12. Global Pulmonary Arterial Hypertension Treatment Market Share by Players (2018-2024)
Table 13. Global Top Pulmonary Arterial Hypertension Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension Treatment as of 2022)
Table 14. Ranking of Global Top Pulmonary Arterial Hypertension Treatment Companies by Revenue (US$ Million) in 2022
Table 15. Global 5 Largest Players Market Share by Pulmonary Arterial Hypertension Treatment Revenue (CR5 and HHI) & (2018-2024)
Table 16. Global Key Players of Pulmonary Arterial Hypertension Treatment, Headquarters and Area Served
Table 17. Global Key Players of Pulmonary Arterial Hypertension Treatment, Product and Application
Table 18. Global Key Players of Pulmonary Arterial Hypertension Treatment, Date of Enter into This Industry
Table 19. Mergers & Acquisitions, Expansion Plans
Table 20. Global Pulmonary Arterial Hypertension Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 21. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2018-2024)
Table 22. Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 23. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2024-2034)
Table 24. Global Pulmonary Arterial Hypertension Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 25. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2018-2024)
Table 26. Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 27. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2024-2034)
Table 28. North America Pulmonary Arterial Hypertension Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 29. North America Pulmonary Arterial Hypertension Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 30. North America Pulmonary Arterial Hypertension Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 31. North America Pulmonary Arterial Hypertension Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 32. North America Pulmonary Arterial Hypertension Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 33. North America Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 34. North America Pulmonary Arterial Hypertension Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 35. North America Pulmonary Arterial Hypertension Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 36. Europe Pulmonary Arterial Hypertension Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 37. Europe Pulmonary Arterial Hypertension Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 38. Europe Pulmonary Arterial Hypertension Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 39. Europe Pulmonary Arterial Hypertension Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 40. Europe Pulmonary Arterial Hypertension Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 41. Europe Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 42. Europe Pulmonary Arterial Hypertension Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 43. Europe Pulmonary Arterial Hypertension Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 44. Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 45. Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 46. Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 47. Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 48. Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 49. Asia-Pacific Pulmonary Arterial Hypertension Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 50. Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 51. Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue by Region (2024-2034) & (US$ Million)
Table 52. Latin America Pulmonary Arterial Hypertension Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 53. Latin America Pulmonary Arterial Hypertension Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 54. Latin America Pulmonary Arterial Hypertension Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 55. Latin America Pulmonary Arterial Hypertension Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 56. Latin America Pulmonary Arterial Hypertension Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 57. Latin America Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 58. Latin America Pulmonary Arterial Hypertension Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 59. Latin America Pulmonary Arterial Hypertension Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 60. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 61. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 62. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 63. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 64. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 65. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 66. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 68. GSK Company Details
Table 69. GSK Business Overview
Table 70. GSK Pulmonary Arterial Hypertension Treatment Product and Services
Table 71. GSK Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 72. GSK Pulmonary Arterial Hypertension Treatment SWOT Analysis
Table 73. GSK Recent Development
Table 74. Eli Lilly and Company Company Details
Table 75. Eli Lilly and Company Business Overview
Table 76. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product and Services
Table 77. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 78. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment SWOT Analysis
Table 79. Eli Lilly and Company Recent Development
Table 80. Pfizer Inc Company Details
Table 81. Pfizer Inc Business Overview
Table 82. Pfizer Inc Pulmonary Arterial Hypertension Treatment Product and Services
Table 83. Pfizer Inc Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 84. Pfizer Inc Pulmonary Arterial Hypertension Treatment SWOT Analysis
Table 85. Pfizer Inc Recent Development
Table 86. Actelion Inc Company Details
Table 87. Actelion Inc Business Overview
Table 88. Actelion Inc Pulmonary Arterial Hypertension Treatment Product and Services
Table 89. Actelion Inc Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 90. Actelion Inc Pulmonary Arterial Hypertension Treatment SWOT Analysis
Table 91. Actelion Inc Recent Development
Table 92. United Therapeutic Corporation Company Details
Table 93. United Therapeutic Corporation Business Overview
Table 94. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product and Services
Table 95. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 96. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment SWOT Analysis
Table 97. United Therapeutic Corporation Recent Development
Table 98. SteadyMed Ltd Company Details
Table 99. SteadyMed Ltd Business Overview
Table 100. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product and Services
Table 101. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 102. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment SWOT Analysis
Table 103. SteadyMed Ltd Recent Development
Table 104. Gilead Sciences, Inc Company Details
Table 105. Gilead Sciences, Inc Business Overview
Table 106. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product and Services
Table 107. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 108. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment SWOT Analysis
Table 109. Gilead Sciences, Inc Recent Development
Table 110. Teva Pharmaceuticals Inc Company Details
Table 111. Teva Pharmaceuticals Inc Business Overview
Table 112. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Product and Services
Table 113. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 114. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment SWOT Analysis
Table 115. Teva Pharmaceuticals Inc Recent Development
Table 116. Bayer AG Company Details
Table 117. Bayer AG Business Overview
Table 118. Bayer AG Pulmonary Arterial Hypertension Treatment Product and Services
Table 119. Bayer AG Pulmonary Arterial Hypertension Treatment Revenue in Pulmonary Arterial Hypertension Treatment Business (2018-2024) & (US$ Million)
Table 120. Bayer AG Pulmonary Arterial Hypertension Treatment SWOT Analysis
Table 121. Bayer AG Recent Development
Table 122. Pulmonary Arterial Hypertension Treatment Market Trends
Table 123. Pulmonary Arterial Hypertension Treatment Market Drivers
Table 124. Pulmonary Arterial Hypertension Treatment Market Challenges
Table 125. Pulmonary Arterial Hypertension Treatment Market Restraints
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Pulmonary Arterial Hypertension Treatment Product Picture
Figure 2. Global Pulmonary Arterial Hypertension Treatment Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Pulmonary Arterial Hypertension Treatment Market Share by Type: 2022 VS 2034
Figure 4. Vasodilators Features
Figure 5. Phosphodiesterase 5 (PDE 5) Inhibitors Features
Figure 6. Endothelin Receptor Antagonists (ERA) Features
Figure 7. Soluble Guanylate Cyclase (SGC) Stimulator Features
Figure 8. Global Pulmonary Arterial Hypertension Treatment Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 9. Global Pulmonary Arterial Hypertension Treatment Market Share by Application: 2022 VS 2034
Figure 10. Hospital Pharmacies
Figure 11. Retail Pharmacies
Figure 12. Online Pharmacies
Figure 13. Pulmonary Arterial Hypertension Treatment Report Years Considered
Figure 14. Global Pulmonary Arterial Hypertension Treatment Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Pulmonary Arterial Hypertension Treatment Market Size 2018-2034 (US$ Million)
Figure 16. Global Pulmonary Arterial Hypertension Treatment Market Size Market Share by Region: 2022 VS 2034
Figure 17. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Region in 2018 VS 2022
Figure 18. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share Forecast by Region (2024-2034)
Figure 19. Global Top 10 Pulmonary Arterial Hypertension Treatment Countries Ranking by Market Size (US$ Million) in 2022
Figure 20. Global Pulmonary Arterial Hypertension Treatment Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 21. Global Pulmonary Arterial Hypertension Treatment Market Share by Players in 2022
Figure 22. Global Top Pulmonary Arterial Hypertension Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension Treatment as of 2022)
Figure 23. The Top 10 and 5 Players Market Share by Pulmonary Arterial Hypertension Treatment Revenue in 2022
Figure 24. North America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Company in 2022
Figure 25. North America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2018-2034)
Figure 26. North America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2018-2034)
Figure 27. North America Pulmonary Arterial Hypertension Treatment Revenue Share by Country (2018-2034)
Figure 28. United States Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 29. Canada Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 30. Europe Pulmonary Arterial Hypertension Treatment Revenue Market Share by Company in 2022
Figure 31. Europe Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2018-2034)
Figure 32. Europe Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2018-2034)
Figure 33. Europe Pulmonary Arterial Hypertension Treatment Revenue Share by Country (2018-2034)
Figure 34. Germany Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 35. France Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 36. UK Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 37. Italy Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 38. Russia Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 39. Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue Market Share by Company in 2022
Figure 40. Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2018-2034)
Figure 41. Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2018-2034)
Figure 42. Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue Share by Region (2018-2034)
Figure 43. China Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 44. Japan Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 45. South Korea Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 46. India Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 47. Australia Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 48. China Taiwan Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 49. Indonesia Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 50. Thailand Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 51. Malaysia Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 52. Latin America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Company in 2022
Figure 53. Latin America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2018-2034)
Figure 54. Latin America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2018-2034)
Figure 55. Latin America Pulmonary Arterial Hypertension Treatment Revenue Share by Country (2018-2034)
Figure 56. Mexico Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 57. Brazil Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 58. Argentina Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 59. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue Market Share by Company in 2022
Figure 60. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue Market Share by Type (2018-2034)
Figure 61. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2018-2034)
Figure 62. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue Share by Country (2018-2034)
Figure 63. Turkey Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 64. Saudi Arabia Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 65. UAE Pulmonary Arterial Hypertension Treatment Revenue (2018-2034) & (US$ Million)
Figure 66. GSK Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 67. Eli Lilly and Company Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 68. Pfizer Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 69. Actelion Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 70. United Therapeutic Corporation Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 71. SteadyMed Ltd Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 72. Gilead Sciences, Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 73. Teva Pharmaceuticals Inc Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 74. Bayer AG Revenue Growth Rate in Pulmonary Arterial Hypertension Treatment Business (2018-2024)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed